Dr. Segall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
175 Country Club Dr 100a
Stockbridge, GA 30281Phone+1 770-507-0707Fax+1 770-507-1539
Education & Training
University of Colorado School of Medicine/National Jewish Health (Adult)Fellowship, Allergy and Immunology, 1977 - 1979
USA HealthResidency, Internal Medicine, 1975 - 1977
Louisiana State University School of MedicineInternship, Transitional Year, 1973 - 1974
University of Alabama School of MedicineClass of 1973
Certifications & Licensure
GA State Medical License 1979 - 2025- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification RcopiaMU EHR, DrFirst.com, Inc., 2012-2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes Start of enrollment: 2014 May 01
- CSD170201: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products Start of enrollment: 2017 May 08
- CSD170202: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products Start of enrollment: 2017 May 08
Publications & Presentations
PubMed
- 31 citationsImmunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial.Timo Vesikari, Adam Finn, Pierre Van Damme, Isabel Leroux-Roels, Geert Leroux-Roels
JAMA Network Open. 2021-10-01 - 34 citationsImmunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.Timo Vesikari, Joanne M. Langley, Nathan Segall, Brian J. Ward, Curtis Cooper
The Lancet. Infectious Diseases. 2021-05-11 - 6094 citationsEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Karen L. Kotloff, Sharon E. Frey
The New England Journal of Medicine. 2021-02-04
Press Mentions
Umbreen S. Lodi, MD, an Allergist and Immunologist with Grady Memorial Hospital and Piedmont Atlanta HospitalDecember 22nd, 2020- COVID Vaccine Trials Lack Important Study ParticipantsSeptember 10th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
